BIOA (BioAge Labs) Earnings per share for the last four quarters

BioAge Labs Inc. (BIOA) - corporate logo

BioAge Labs, Inc. (BIOA) relies on venture capital, as the clinical testing stage precludes the existence of profitable products. Meanwhile, business resilience is ensured through diversified raw material supply chains. This EPS (TTM) price chart, which clearly demonstrates changes, shows a value of -20.50. Investors value the brand for its innovative approach to longevity and the use of advanced data analytics.

BIOA bioagelabs.com Net earnings per share (EPS TTM) (11/23/2025 - 11/16/2026)

BIOA (BioAge Labs, Inc.): analytical breakdowns and indicator data

- price and consensus price forecast:
- business market valuation indicators:
Fundamental company valuation:BIOA (BioAge Labs)
Core merchandise of BioAge Labs, Inc

Year-over-year (YoY) EPS growth (TTM) measures the percentage change in earnings per share over the trailing twelve months relative to the same period last year. By analyzing historical YoY EPS growth over the past 12 months, an investor assesses the scaling rate of net income. Mathematically, this metric reflects capital generation efficiency; however, for BioAge Labs, Inc. (BIOA), it remains nominal. Given the absence of commercial sales and dependence on FDA regulators, this indicator merely captures the clinical development stage of the biotech ecosystem.

Competitor analysis

Net earnings per one share for the last twelve months Ascendis Pharma Inc.|MDGL (Madrigal Pharmaceuticals, Inc.) - Net earnings per share for the last 12 months|CORT: Earnings per share for the last four quarters|RYTM (Rhythm Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Akero Therapeutics|Net earnings per share (EPS TTM) MTSR|Earnings per share for the last twelve months MLTX (MoonLake Immunotherapeutics AG)|Earnings per share for the last twelve months crinetics.com CRNX|NewAmsterdam Pharma Corp (NAMS) - Net earnings per one share for the last twelve months|SLNO - Earnings per share for the last twelve months|FOLD: Earnings per share for the last twelve months|ETNB: Net earnings per share (EPS TTM)|AGIO - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Structure Corp|MiMedx Corp (MDXG) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months rezolutebio.com (RZLT)|Net earnings per share for the last 12 months lexpharma.com LXRX|Net earnings per share (EPS TTM) MBX (MBX Biosciences)|Altimmune Corp - Earnings per share for the last twelve months|Aardvark Therapeutics Inc. - Net earnings per share (EPS TTM)|SGMT - Net earnings per share (EPS TTM)|Biomea Fusion Inc (BMEA) - Earnings per share for the last twelve months|QNCX - Net earnings per share for the last four quarters|GUTS (Fractyl Health Inc.) - Net earnings per share (EPS TTM)|VTVT: Earnings per share for the trailing year|Net earnings per share (EPS TTM) ATPC|Net earnings per share for the last four quarters Pluri Inc|Net earnings per share (EPS TTM) SYBX (Synlogic Corp)|Net earnings per share for the last four quarters lipocine.com (LPCN)|MTNB - Earnings per share for the last twelve months|Earnings per share for the trailing year SPRB (Spruce Biosciences)|GLTO (Galecto Corp) - Net earnings per share for the last 12 months|Carmell Corp - Earnings per share for the trailing year|LUMO (Lumos Therapeutics) - Net earnings per share (EPS TTM)|ONVO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) RDUS